Allison Dorval - 11 Jun 2026 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Reporting relationship: Director
Issuer ticker: PBYI
Reported as of: 11 Jun 2026
Net transaction value: -$83,579
SEC form: 4
Accepted by SEC: 15 Jun 2026, 20:09:07 UTC
Prior SEC filing: 28 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Gordon Esplin as attorney-in-fact for Allison Dorval

Key filing fact

Allison Dorval filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 15 Jun 2026.

Key facts

This page summarizes Allison Dorval's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 20:09.

Change

Previous filing in this sequence was filed on 28 Jul 2025.
Current net transaction value: -$83,579.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001625110 Primary reporting owner

Dorval Allison

Relationship: Director
Address: C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 1700, LOS ANGELES
Signature: /s/ Gordon Esplin as attorney-in-fact for Allison Dorval
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PBYI transaction

Common Stock

Award

Transaction value
Shares: +27,000
Change %: +36%
Price: $0.000000^*
Shares after: 102,390
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1

PBYI transaction

Common Stock

Sale

Transaction value: $83,579
Shares: -11,610
Change %: -11%
Price: $7.20
Shares after: 90,780
Date: 12 Jun 2026
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.

Footnote F2

Adoption date of referenced 10b5-1(c) plan is: 03-12-2025

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.